HC Wainwright Reaffirms Buy Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $3.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 40.19% from the company’s previous close. HC Wainwright also issued estimates for Vor Biopharma’s FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.21 EPS.

Other research analysts have also issued reports about the stock. Baird R W lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Wedbush reissued an “outperform” rating on shares of Vor Biopharma in a report on Thursday, June 26th. Citizens Jmp lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Friday, May 9th. JMP Securities reissued a “market perform” rating and issued a $6.00 target price on shares of Vor Biopharma in a report on Friday, May 9th. Finally, Jones Trading lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.07.

Vor Biopharma Stock Performance

VOR stock opened at $2.14 on Thursday. The firm has a fifty day moving average price of $1.59 and a 200 day moving average price of $1.04. Vor Biopharma has a fifty-two week low of $0.13 and a fifty-two week high of $3.29. The firm has a market cap of $271.01 million, a PE ratio of -1.30 and a beta of 2.06.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Money Concepts Capital Corp boosted its stake in Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after buying an additional 26,535 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Vor Biopharma during the second quarter worth $66,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Vor Biopharma during the first quarter worth $100,000. Finally, Trustees of Columbia University in the City of New York bought a new stake in shares of Vor Biopharma during the fourth quarter worth $102,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.